#United States #Robbins Geller #San Diego #Class Action #Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Investors Urged to Act by Tomorrow's Deadline

As legal battles unfold in the complex world of pharmaceuticals, investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) find themselves at a critical junction. Robbins Geller Rudman & Dowd LLP has recently announced that those who purchased or acquired Regeneron common stock between August 1, 2025, and May 15, 2026, have until tomorrow, September 14, 2026, to step forward as lead plaintiffs in a class action lawsuit against the company.

In the case titled Cheatham v. Regeneron Pharmaceuticals, Inc., allegations have arisen regarding misleading statements made by the company and its executives during the class period. The accusations claim that Regeneron not only provided false information regarding the success metrics of its Phase III trial for Fianlimab, also known as Libtayo, but they also created an environment that minimized the potential risks associated with the trial’s objective.

The Allegations Unraveled

Investors are encouraged to understand the core allegations surrounding this class action. During the period in question, Regeneron purportedly allowed the impression that it possessed solid evidence validating their claims about the trial's success. However, crucial details about the inherent risks related to the study's statistical legitimacy were allegedly omitted or downplayed. The firm's preliminary assumptions regarding the trial were deemed to be deeply flawed, raising serious doubts about its conclusions and outcomes.

One particularly alarming moment occurred during Regeneron’s first-quarter earnings call on April 29, 2026. The announcement revealed discrepancies within the Phase III trial, indicating modifications to the criteria for evaluating patients eligible for analysis. This news triggered a swift and significant decline of more than 6% in Regeneron’s stock price.

The situation worsened after a press release shared on May 15, 2026, indicated that the Phase 3 trial of Fianlimab failed to achieve its primary endpoint concerning improvement in progression-free survival (PFS). This information plunged Regeneron’s stock value by nearly 10%, as outlined in the allegations.

Navigating the Class Action Process

Given these developments, the law provides an avenue for affected investors. The Private Securities Litigation Reform Act of 1995 allows any investor who acquired Regeneron’s common stock during the specified class period to apply for the role of lead plaintiff. This position is typically granted to an individual with the most considerable financial interest, who can adequately represent the interests of the class.

The lead plaintiff becomes the figurehead of the group, managing the litigation process and directing the course of the class action lawsuit. Importantly, choosing to become the lead plaintiff does not affect a participant’s ability to recover any potential future compensation as part of the class.

About Robbins Geller

Robbins Geller Rudman & Dowd LLP stands out as a leading law firm in cases involving securities fraud and shareholder rights. With a long history of representing investors, the firm significantly impacted the realm of class action recoveries, ranking first in investor recoveries according to the latest ISS Securities Class Action Services report. They have historically achieved notable settlements, reaffirming their commitment to safeguarding investor interests.

For stakeholders looking to make their voices heard, it’s crucial to act swiftly. Investors considering stepping up as lead plaintiffs are urged to reach out to Robbins Geller’s legal team for guidance. Informative resources and avenues for communication have been made available through their designated contact points.

As the deadline approaches, affected investors are reminded that the time to act is now. Through steadfast legal representation and a unified effort, there exists the potential to address and rectify the grievances stemming from this high-stakes environment. The consequences of inaction could be detrimental, highlighting the importance of leading the charge towards justice.